News & events

News & events

Filter by:
  • News

VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery

Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation,...

  • Management TeamNews

BioStock interview with CEO John Glasspool on VMX-C001 at BioCapital Europe

  • Scientific publications

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to...

  • News

VarmX raises seed capital for development of VMX-C001

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis,...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio